Release 17th June, 2020
Hope 1
tincture with a THC:CBD ratio of 1:1 with Eucalyptol, Valencene and Alpha-Pinene terpenes
Hope 2
2 tincture with a THC:CBD ratio of 5:1 with beta-Caryophyllene, Myrcene and Alpha-Bisabolol terpenes
Recent white paper on a 68 day averaged dosing program across 50 patients in Penn State....through the 'Hope grows for Autism' network
Early days but extremely positive outcomes across the group and immediate families / caregivers
Significant improvements in patient irritability (68%), meltdowns (60%), aggression (55%), anxiety (49%) as well as capacity to focus (38%); while 69% of participants reported an improved quality of life for the patient. In addition, 58% reported improved quality of life for the entire family.” In other words, a THC:CBD tincture of varying doses and a rich terpene profile produced significant improvements and quality of life for the patients. 26% of patients used only HOPE 1, 54% of patients used only HOPE 2, and 20% of patients used both HOPE 1 and HOPE 2.
According to the data, 0% of patients reported the patient’s symptoms worsening. This is a great example of the cannabis plant’s gentle properties and minimal side effects. Additionally, less than 30% of participants reported no change in symptoms for anxiety, aggression, meltdowns, and irritability, with roughly 42% of participants reporting no change in the patient’s ability to focus. The majority of patients, however, noted significant improvement, with a small percentage noticing some improvement.
Expand
